logo
  • Home
  • News
Menu

Amneal Receives Approval for Generic TobraDex®

Home / Stock Analysis / Amneal Receives Approval for Generic TobraDex®
Article feature image

Amneal Receives Approval for Generic TobraDex®

19 Jul Stock Analysis

BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic…

Click here to view the original article.

Tags:
Business Wire, Global
Facebook Google+ Twitter Pinterest
  Previous
Next  

Related Posts

1585186556238.jpeg
+

With A 28% Price Drop For The Trade Desk, Inc. (NASDAQ:TTD) You’ll Still Get What You Pay For

09 Aug Stock Analysis
1585186668959.jpeg
+

Selling Expensify Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders

09 Aug Stock Analysis

recent post

  • 68979cbe644555596bb54271_68979cbd87b4077a577e4e21_lastImage.png

    BlockDAG: A New Era for Crypto

    Aug 09 2025
  • 689799fd28be8d41e23deb6b_6897995787664d20bfcd3471_lastImage.png

    Litecoin Investment Horizons Illuminate the Crypto

    Aug 09 2025
  • 1754763180448_now_hallie_wnba_sextoys_crypto_250809_1920x1080-7wjbwp.jpg

    Crypto group behind sex toys being

    Aug 09 2025
  • 5jmwVa5gMjYJsoge5ab2wg.jpg

    Crypto hacker steals $14.5 billion in

    Aug 09 2025
  • 1-220.jpg

    Crypto Market Cap at $3.9 Trillion,

    Aug 09 2025

Categories

  • Business
  • Crypto News
  • Investing Strategy
  • People
  • Stock Analysis

©2019.  All Rights Reserved.